Conversion of a portion of the loans from Highbridge and Whitebox and information on the total number of voting rights (denominator)

,

Liege, Belgium, 14 September 2022 – 17:45 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to Women’s Health, today announces that, following the first drawdown by the Company under the loan facility concluded with funds managed by Highbridge Capital Management, LLC (“Highbridge”) and funds managed by Whitebox Advisors, LLC (“Whitebox”, and together with Highbridge, each a “Lender”), another portion of the loans was contributed in kind by Whitebox against the issuance of new shares.